Baidu
map

NEJM:单克隆抗体AZD7442可有效降低新冠肺炎易感人群感染风险

2022-06-13 zhangfan MedSci原创

对于新冠肺炎易感人群,单次AZD7442治疗后可提供长达180天的保护作用,且安全性良好

接种疫苗大幅降低了全球Covid-19疾病负担,但对于部分特殊群体,如免疫功能低下和无法接种疫苗的人群,有效的新冠肺炎药物预防手段仍十分必要。单克隆抗体可有效预防病毒感染,且不依懒于患者基础免疫状态,是一种极具潜力的新冠肺炎预防手段。单克隆抗体AZD7442由SARS-CoV-2病毒中和抗体Tixagevimab和Cilgavimab组成,在动物模型中表现出良好的新冠肺炎预防和治疗作用。近日研究人员开展III期临床研究,考察了AZD7442对新冠肺炎易感人群的保护效果。

本次III期临床研究中,招募接种疫苗后反应不足人群或高风险暴露人群参与研究,接受单剂量300 mg AZD7442或生理盐水安慰剂,初步随访长达183天。研究的主要疗效终点是干预后183天内出现有症状的Covid-19疾病。

共有5197名参与者,其中AZD7442组3460人,安慰剂组1737人。AZD7442组参与者中有1221名(35.3%)报告了至少1次不良事件,而安慰剂组参与者中有593名(34.2%),其中大多数不良事件为轻度或中度。AZD7442组受试者中有8名(0.2%)出现有症状Covid-19,而安慰剂组受试者中有17名(1.0%,AZD7442治疗后相对风险降低76.7%)。安慰剂组有5例重症Covid-19病例和2例Covid-19死亡病例。

研究认为,对于新冠肺炎易感人群,单次AZD7442治疗后可提供长达180天的保护作用,且安全性良好。

原始出处:

Myron J. Levin et al. Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19. N Engl J Med,June 9, 2022.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1660278, encodeId=da8b16602e8e6, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Thu Sep 15 00:53:55 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714940, encodeId=09ca1e1494025, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Wed Feb 22 13:53:55 CST 2023, time=2023-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061113, encodeId=3fcc20611139e, content=<a href='/topic/show?id=f4e2596557e' target=_blank style='color:#2F92EE;'>#易感人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59655, encryptionId=f4e2596557e, topicName=易感人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Nov 15 18:53:55 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243756, encodeId=931f1243e56f6, content=NEJM上果然牛,感谢梅斯更新及时, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=小元, createdTime=Mon Jun 13 23:53:55 CST 2022, time=2022-06-13, status=1, ipAttribution=)]
    2022-09-15 aids221
  2. [GetPortalCommentsPageByObjectIdResponse(id=1660278, encodeId=da8b16602e8e6, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Thu Sep 15 00:53:55 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714940, encodeId=09ca1e1494025, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Wed Feb 22 13:53:55 CST 2023, time=2023-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061113, encodeId=3fcc20611139e, content=<a href='/topic/show?id=f4e2596557e' target=_blank style='color:#2F92EE;'>#易感人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59655, encryptionId=f4e2596557e, topicName=易感人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Nov 15 18:53:55 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243756, encodeId=931f1243e56f6, content=NEJM上果然牛,感谢梅斯更新及时, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=小元, createdTime=Mon Jun 13 23:53:55 CST 2022, time=2022-06-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1660278, encodeId=da8b16602e8e6, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Thu Sep 15 00:53:55 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714940, encodeId=09ca1e1494025, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Wed Feb 22 13:53:55 CST 2023, time=2023-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061113, encodeId=3fcc20611139e, content=<a href='/topic/show?id=f4e2596557e' target=_blank style='color:#2F92EE;'>#易感人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59655, encryptionId=f4e2596557e, topicName=易感人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Nov 15 18:53:55 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243756, encodeId=931f1243e56f6, content=NEJM上果然牛,感谢梅斯更新及时, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=小元, createdTime=Mon Jun 13 23:53:55 CST 2022, time=2022-06-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1660278, encodeId=da8b16602e8e6, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Thu Sep 15 00:53:55 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714940, encodeId=09ca1e1494025, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Wed Feb 22 13:53:55 CST 2023, time=2023-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061113, encodeId=3fcc20611139e, content=<a href='/topic/show?id=f4e2596557e' target=_blank style='color:#2F92EE;'>#易感人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59655, encryptionId=f4e2596557e, topicName=易感人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Nov 15 18:53:55 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243756, encodeId=931f1243e56f6, content=NEJM上果然牛,感谢梅斯更新及时, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=小元, createdTime=Mon Jun 13 23:53:55 CST 2022, time=2022-06-13, status=1, ipAttribution=)]
    2022-06-13 小元

    NEJM上果然牛,感谢梅斯更新及时

    0

相关资讯

CMI:注射卡介苗疫苗可以减少新冠肺炎疫情期间医护人员的缺勤率

卡介苗(BCG)广泛用于预防结核病,也对其他传染病提供非特异性效应。

中国台湾地区6日新增53023例新冠肺炎确诊病例,151例死亡,确诊数字有所下降,目前总死亡率为0.126%

台湾地区流行疫情指挥中心今(6日)公布,岛内新增53023例新冠肺炎确诊病例,分别为52992例本地确诊及31例境外输入,另新增151例死亡。

JAAD:托法替尼治疗斑秃与新冠肺炎感染期间不良事件无关

尽管口服Janus激酶抑制剂(JAKIs)越来越成为斑秃(AA)的首选治疗药物,但服用JAKI的斑秃患者中新冠肺炎感染的临床结果以前尚未报道。本文就相关问题进行了研究。

国家卫健委:昨日新增本土确诊病例20+120例(2022.6.3)

6月2日0—24时,31个省(自治区、直辖市)和新疆生产建设兵团报告新增确诊病例37例。其中境外输入病例17例(福建7例,广西4例,上海2例,广东2例,山西1例,重庆1例);本土病例20例

抗 COVID-19 的中药:肠道菌群的作用

2019冠状病毒病(COVID-19)是一种由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的急性呼吸道传染病,已成为全球关注的公共卫生问题。

Pediatrics:新冠肺炎疫情期间儿科急诊科脓毒症筛查工具的准确性

幸存败血症运动建议对急性不适的儿童(如儿科急诊(ed)的儿童)进行败血症和相关疾病的筛查。

Baidu
map
Baidu
map
Baidu
map